This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (April 2011) (Learn how and when to remove this template message)
|Chemical and physical data|
|Molar mass||617.51 g/mol|
|3D model (JSmol)|
TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.
TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.
- https://web.archive.org/web/20110707065905/http://www.7tm.com/. Archived from the original on July 7, 2011. Retrieved January 18, 2011. Missing or empty
- Hung, M. S.; Chang, C. P.; Li, T. C.; Yeh, T. K.; Song, J. S.; Lin, Y.; Wu, C. H.; Kuo, P. C.; Amancha, P. K.; Wong, Y. C.; Hsiao, W. C.; Chao, Y. S.; Shia, K. S. (2010). "Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist". ChemMedChem. 5 (9): 1439–1443. PMID 20652930. doi:10.1002/cmdc.201000246.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|